GAM
IOVA icon

Gould Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Gould Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,735
Closed -$111K – 180
2026
Q1 		$111K Hold
31,735
– – 0.02% 171
2025
Q4 		$86.6K Buy
31,735
+20,000
+170% +$46.3K 0.02% 167
2025
Q3 		$25.5K Hold
11,735
– – ﹤0.01% 169
2025
Q2 		$20.2K Hold
11,735
– – ﹤0.01% 166
2025
Q1 		$39.1K Buy
+11,735
New +$60.5K 0.01% 160

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Gould Asset Management's IOVA Position: Q2 2026 in Review

Gould Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 31,735 shares — an estimated $111K sold.

Gould Asset Management first reported a position in IOVA in Q1 2025 and held it in 5 quarters. The position peaked at $111K in Q1 2026. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Gould Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Gould Asset Management sold 31,735 Iovance Biotherapeutics shares in Q2 2026, an estimated $111K.
  • Gould Asset Management first reported a position in Iovance Biotherapeutics in Q1 2025 and held it in 5 quarters.
  • Gould Asset Management's Iovance Biotherapeutics position peaked at $111K in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Gould Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.